## Edgar Filing: CUMBERLAND PHARMACEUTICALS INC - Form 4

Check this box if no longer subject to Section 16. Form 4 or	D STATES SECU	URITIES A ashington, NGES IN SECUR	D.C. 20 BENEFI ITIES	549 [CIA]	L OW	NERSHIP OF		rs per		
abligations	7(a) of the Public 30(h) of the	Utility Hold	ling Con	ipany	Act of	f 1935 or Section	n			
(Print or Type Responses)										
1. Name and Address of Reportin Bonner Michael	Symbo CUM	2. Issuer Name <b>and</b> Ticker or Trading Symbol CUMBERLAND PHARMACEUTICALS INC [CPIX]				5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
(Last) (First) (Middle) 3. Date of Earliest Transaction (Month/Day/Year) 2525 WEST END AVENUE, SUITE 04/06/2016 950					Director 10% Owner X_ Officer (give title Other (specify below) below) Chief Financial Officer					
(Street)		4. If Amendment, Date Original Filed(Month/Day/Year)				Applicable Line) _X_ Form filed by (	l or Joint/Group Filing(Check ne) ed by One Reporting Person d by More than One Reporting			
NASHVILLE, TN 37203						Person		Porting		
(City) (State)	(Zip) Ta	ble I - Non-D	erivative s	Securi	ties Acc	uired, Disposed of	f, or Beneficial	ly Owned		
	Date 2A. Deemed ar) Execution Date, any (Month/Day/Yea	Code	on(A) or D (D) (Instr. 3,	4 and (A) or	d of		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)			
Common 04/06/2016 Stock		A	5,000 (1)	A	\$ 4.34	11,000	D			

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	4. Transacti Code (Instr. 8)	5. orNumber of Derivativ Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	5		Amou Unde Secur	le and unt of rlying rities : 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secur Bene Owne Follo Repo Trans (Instr
			Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

## Edgar Filing: CUMBERLAND PHARMACEUTICALS INC - Form 4

## **Reporting Owners**

Reporting Owner Name / Address		Relationships						
		irector	10% Owner	Officer	Other			
Bonner Michael 2525 WEST END AVENUE, SUITE 950 NASHVILLE, TN 37203				Chief Financial Officer				
Signatures								
Michael Bonner 04	/08/2016							

\*\*Signature of Reporting Person Date

## **Explanation of Responses:**

- If the form is filed by more than one reporting person, see Instruction 4(b)(v). \*
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Restricted stock award will vest 100% on March 18, 2020.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.